JP2018508516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508516A5 JP2018508516A5 JP2017546075A JP2017546075A JP2018508516A5 JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5 JP 2017546075 A JP2017546075 A JP 2017546075A JP 2017546075 A JP2017546075 A JP 2017546075A JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5
- Authority
- JP
- Japan
- Prior art keywords
- eribulin
- breast cancer
- medicament
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 19
- 206010006187 Breast cancer Diseases 0.000 claims 15
- 208000026310 Breast neoplasm Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229960003649 eribulin Drugs 0.000 claims 14
- 229960002621 pembrolizumab Drugs 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229940124060 PD-1 antagonist Drugs 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 229960000439 eribulin mesylate Drugs 0.000 claims 4
- 230000002055 immunohistochemical effect Effects 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128373P | 2015-03-04 | 2015-03-04 | |
| US62/128,373 | 2015-03-04 | ||
| US201562264068P | 2015-12-07 | 2015-12-07 | |
| US62/264,068 | 2015-12-07 | ||
| PCT/US2016/020734 WO2016141209A1 (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508516A JP2018508516A (ja) | 2018-03-29 |
| JP2018508516A5 true JP2018508516A5 (OSRAM) | 2019-04-18 |
| JP6951248B2 JP6951248B2 (ja) | 2021-10-20 |
Family
ID=55586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546075A Active JP6951248B2 (ja) | 2015-03-04 | 2016-03-03 | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10945990B2 (OSRAM) |
| EP (1) | EP3265122B1 (OSRAM) |
| JP (1) | JP6951248B2 (OSRAM) |
| KR (1) | KR20170122810A (OSRAM) |
| CN (1) | CN107810013B (OSRAM) |
| AU (1) | AU2016226157B2 (OSRAM) |
| BR (1) | BR112017018872A2 (OSRAM) |
| CA (1) | CA2978311A1 (OSRAM) |
| IL (1) | IL254133B (OSRAM) |
| MX (1) | MX386547B (OSRAM) |
| RU (1) | RU2737216C2 (OSRAM) |
| SG (1) | SG11201706872SA (OSRAM) |
| WO (1) | WO2016141209A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| KR101495951B1 (ko) | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| AU2016226157B2 (en) | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HK1252026A1 (zh) * | 2015-06-11 | 2019-05-10 | Bionomics Limited | 药物组合及其应用 |
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| WO2018071792A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| WO2018075740A1 (en) * | 2016-10-21 | 2018-04-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist |
| WO2019017497A1 (en) * | 2017-07-21 | 2019-01-24 | Eisai R&D Management Co., Ltd. | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| JP7329860B2 (ja) * | 2018-06-15 | 2023-08-21 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ｓ－エクオールを用いた乳癌の治療及び予防方法 |
| AU2019285641A1 (en) | 2018-06-15 | 2021-04-08 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| JP2022553421A (ja) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | がんの処置のための方法および組成物 |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US8097648B2 (en) * | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| IL139960A0 (en) * | 1998-06-17 | 2002-02-10 | Eisai Co Ltd | Macrocylic analogs and methods of their use and preparation |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2578576B9 (en) | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| SG182612A1 (en) | 2010-01-26 | 2012-08-30 | Eisai R&D Man Co Ltd | Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs |
| JP2014508165A (ja) | 2011-03-02 | 2014-04-03 | モルフォテック、インク． | 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与 |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| ES2644022T3 (es) | 2013-03-14 | 2017-11-27 | Bristol-Myers Squibb Company | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| CN105283180A (zh) | 2013-06-11 | 2016-01-27 | 诺华股份有限公司 | Pi3k抑制剂与微管去稳定剂的药物组合 |
| KR102265952B1 (ko) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 |
| US9457019B2 (en) * | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3114144A1 (en) * | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| KR20170039096A (ko) | 2014-05-28 | 2017-04-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료에 있어서 에리불린의 용도 |
| AU2016226157B2 (en) | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
-
2016
- 2016-03-03 AU AU2016226157A patent/AU2016226157B2/en not_active Ceased
- 2016-03-03 WO PCT/US2016/020734 patent/WO2016141209A1/en not_active Ceased
- 2016-03-03 CA CA2978311A patent/CA2978311A1/en not_active Abandoned
- 2016-03-03 CN CN201680025588.3A patent/CN107810013B/zh not_active Expired - Fee Related
- 2016-03-03 SG SG11201706872SA patent/SG11201706872SA/en unknown
- 2016-03-03 MX MX2017011206A patent/MX386547B/es unknown
- 2016-03-03 EP EP16710891.9A patent/EP3265122B1/en not_active Revoked
- 2016-03-03 US US15/554,540 patent/US10945990B2/en active Active
- 2016-03-03 BR BR112017018872A patent/BR112017018872A2/pt not_active IP Right Cessation
- 2016-03-03 JP JP2017546075A patent/JP6951248B2/ja active Active
- 2016-03-03 KR KR1020177027617A patent/KR20170122810A/ko not_active Ceased
- 2016-03-03 RU RU2017132877A patent/RU2737216C2/ru active
-
2017
- 2017-08-24 IL IL254133A patent/IL254133B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508516A5 (OSRAM) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018512391A5 (OSRAM) | ||
| JP7578643B2 (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| US20230103007A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2019530706A5 (OSRAM) | ||
| JP2019536805A5 (OSRAM) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2017506227A5 (OSRAM) | ||
| ES2922378T3 (es) | C. novyi para el tratamiento de tumores sólidos en seres humanos | |
| JP2016530280A5 (OSRAM) | ||
| JP2014511383A5 (OSRAM) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| KR20190025733A (ko) | 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물 | |
| JP2015517523A5 (OSRAM) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| JPWO2019241442A5 (OSRAM) | ||
| JP2021505669A5 (OSRAM) | ||
| AU2023336057A1 (en) | Dosage regimens of estrogen receptor degraders | |
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| JP2019501957A5 (OSRAM) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| JP2018522881A5 (OSRAM) | ||
| TWI707681B (zh) | 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途 |